Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
In this study, MGCD265, a new anticancer drug under investigation, is given daily on a 7 days
on / 7 days off schedule to patients with advanced malignancies to study its safety profile.